TECX (Tectonic Therapeutic) Land And Improvements : $0.00 Mil (As of Mar. 2025)

View and export this data going back to 2024. Start your Free Trial

What is Tectonic Therapeutic Land And Improvements?

Tectonic Therapeutic's land and improvements for the quarter that ended in Mar. 2025 was $0.00 Mil.

Tectonic Therapeutic Land And Improvements Historical Data

The historical data trend for Tectonic Therapeutic's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tectonic Therapeutic Land And Improvements Chart

Tectonic Therapeutic Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

Land And Improvements

Tectonic Therapeutic Quarterly Data
	Dec21	Dec22	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Land And Improvements	Get a 7-Day Free Trial					-	-	-	-	-

Tectonic Therapeutic Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Tectonic Therapeutic Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tectonic Therapeutic Inc (NAS:TECX) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

N/A

Address

490 Arsenal Way, Suite 210, Watertown, MA, USA, 02472

Website

https://www.tectonictx.com

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.